Commentary: does immune suppression increase risk of developing acute myeloid leukemia?

Area of Science:

• Oncology
• Immunology
• Transplantation

Background:

• Immune suppression is linked to increased risks of various cancers, including lymphomas and skin cancers.
• However, a connection between immune suppression and acute myeloid leukemia (AML) has not been previously established.
• Experimental data suggest immune suppression might play a role in AML development and that immune stimulation could be therapeutic.

Purpose of the Study:

• To investigate the correlation between immune suppression and the risk of developing acute myeloid leukemia (AML).
• To determine if patients undergoing solid organ transplantation face an elevated risk of AML.

Main Methods:

• Analysis of data from 248,224 solid organ transplant recipients (217,219 kidney, 31,005 heart).
• Calculation of standardized incidence ratios (SIR) for AML in kidney and heart transplant recipients.

Main Results:

• Kidney transplant recipients showed a significantly increased SIR for AML (1.90).
• Heart transplant recipients exhibited a markedly higher SIR for AML (5.1).
• The data indicate a clear association between immune suppression and increased AML risk, escalating with immunosuppression intensity.

Conclusions:

• Immune suppression following solid organ transplantation is associated with a significantly increased risk of developing acute myeloid leukemia (AML).
• The risk of AML is notably higher in heart transplant recipients compared to kidney transplant recipients, potentially due to differences in immunosuppression protocols.
• These findings have implications for understanding AML pathogenesis and developing novel therapeutic strategies, possibly involving immune modulation.